5.5 C
Glasgow
Saturday, November 15, 2025
spot_img

More News

Mechanism behind overactive immune cells revealed​

Jim Cornall -
Why do immune cells that are supposed to eliminate viruses suddenly turn against our own body? There are instances where...

Investigational treatment of autosomal dominant polycystic kidney disease receives orphan drug designation

Jim Cornall -
Calico Life Sciences LLC (Calico) has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug...

World’s first gene-editing therapy for hyperlipidemia

Jim Cornall -
CorrectSequence Therapeutics Co., Ltd. (Correctseq) has announced that the first patient in its Investigator-Initiated Trial (IIT) of the base-editing...

Positive results for Lilly obesity drug

Jim Cornall -
Eli Lilly and Company has announced positive results from a phase 2 trial evaluating the safety and efficacy of...

“Foundational moment for in vivo cell therapy”

Jim Cornall -
CREATE Medicines Inc. has announced first-in-human results from its phase 1 MYE Symphony trial evaluating MT-302, an mRNA-LNP-encoded TROP2-targeted...

Cooperative motor proteins kill cancer cells when dual-inhibited

Jim Cornall -
A research team from The University of Osaka in Japan, in collaboration with the Massachusetts Institute of Technology, has...

SanegeneBio announces collaboration with Lilly

Jim Cornall -
SanegeneBio has announced a global research and licensing collaboration with Eli Lilly and Company. The companies will collaborate to...

Amgen reveals cardiovascular drug results

Jim Cornall -
Amgen has announced results from the phase 3 VESALIUS-CV clinical trial, which showed that Repatha (evolocumab) achieved statistically significant...

Pila Pharma’s capital raise oversubscribed by 293% to fund obesity studies

Jim Cornall -
Biotech company Pila Pharma has completed an oversubscribed share issue on Nasdaq First North in Stockholm. The raised capital will...

Base to Base biotech podcast 34: World Immunization Day and infertility

Jim Cornall -
It’s World Immunization Day on Monday, so we had a chat with Geovax chairman, president and CEO David Dodd,...

Lilly investing $1.2bn in Puerto Rico facility

Jim Cornall -
Eli Lilly and Company has announced a planned investment of more than $1.2bn to expand and modernise its Lilly...

Launch of major diabetes fundraiser

Jim Cornall -
The T1D Fund: A Breakthrough T1D Venture, LLC, an impact investment fund focused on accelerating life-changing solutions to treat,...

The future of in vivo cell engineering?

Jim Cornall -
CREATE Medicines, Inc. has presented new preclinical data for RetroT, the company's fully RNA-encoded, site-specific gene-integration system, at the...

AI-designed alopecia drug completes US phase I trial

Jim Cornall -
AnHorn Medicines has announced positive results from its US phase I clinical trial of AH-001, an AI-generated topical protein...

Valthos raises $30m to build next-generation biodefence

Jim Cornall -
Valthos has raised $30m in seed financing to support the development of next-generation biodefense systems. The funding came from OpenAI...

CAR-T therapy in Korea

Jim Cornall -
Nanjing IASO Biotechnology signed an agreement with Korea's GC Cell to introduce the CAR-T therapy Fucaso (Equecabtagene Autoleucel) to...

Myrio Therapeutics to work with research institutions on solid tumour T-cell immunotherapeutics

admin -
Myrio Therapeutics has announced a collaborative research partnership with the University of Pennsylvania's Perelman School of Medicine and NYU...

Positive topline results for frontotemporal degeneration treatment

Jim Cornall -
Vesper Bio ApS has announced positive topline results from its phase Ib/IIa SORT-IN-2 clinical study evaluating VES001 in asymptomatic...

Lilly and NVIDIA building industry’s most powerful AI supercomputer

Jim Cornall -
Eli Lilly and Company is building the most powerful supercomputer owned and operated by a pharmaceutical company, in collaboration...

New findings pave the way for ear infection vaccine

Jim Cornall -
New findings may lead to the development of a vaccine to protect against a very common type of ear...

Immune checkpoint inhibitors promote tissue repair

Jim Cornall -
Immune checkpoint inhibitors are known as a form of cancer treatment. Researchers at UZH in Switzerland have now identified...

Deeptech Digest is your guide to what's new in at the cutting edge of science technology. A bit of artificial intelligence, some biotech, and all the news and latests developments in the field. If it's deeptech, it's in Deeptech Digest!

Contact us: jim@deeptechdigest.com

© 2023 Ayr Coastal Media